[Translation] A multicenter, randomized, open-label, endpoint-blind, positive drug parallel-controlled, non-inferiority phase III clinical trial of tenecteplase for injection (TNK-tPA) for the treatment of hyperacute (onset <4.5h) ischemic stroke (3T Stroke-Ⅲ)
评价TNK-tPA用于治疗超急性期(发病<4.5h)缺血性卒中的有效性及安全性,为TNK-tPA上市提供依据和数据支持。
[Translation] To evaluate the efficacy and safety of TNK-tPA in the treatment of hyperacute (onset <4.5h) ischemic stroke and provide a basis and data support for the marketing of TNK-tPA.